Brilinta reduces CV events but increases bleeding
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
Read More
Tag: bleeding
EC extends license for Roche/Chugai’s Hemlibra
The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the drug’s treatment scope.
Read More
Use of Roche’s haemophilia A therapy Hemlibra expanded in the US
Roche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors.
Read More
US expands use of Shire’s Vonvendi
US regulators have expended the scope of Shire’s Vonvendi to include perioperative management of bleeding in adults with von Willebrand disease (VWD).
Read More
BMS ties with Janssen on Factor XIa inhibitor programme
Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme.
Read More
New guidelines recommend hysteroscopy test for heavy periods
More women in England and Wales are to be offered a test to better determine the causes of heavy menstrual bleeding, on updated guidelines from the National Institute for Health and Care Excellence.
Read More
EU regulators reviewing Shire’s bleeding disorder drug
European regulators have validated the marketing authorisation application for Shire’s experimental von Willebrand Disease therapy Veyvondi.
Read More
Trial finds higher aspirin bleed risk for elderly
The use of daily aspirin as a blood thinner in people aged over 75 years is linked with a much higher risk of major and potentially fatal stomach bleeds than previously thought.
Read More
Aberdeen Uni leads £1.1m study on bleeding plug
A £1.1-million study led by the University of Aberdeen is trialling a new technique that aims to control life-threatening bleeding in trauma victims.
Read More
FDA nod for CSL’s long-acting haemophilia drug
CSL Behring’s Afstyla has been approved in the US as a long-lasting treatment option for patients with the bleeding disorder haemophilia A.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
